ScholarIQanswers from OpenAlex & ORCID
Alan Kivitz
ResearcherPublications, citations & collaboration network
Alan Kivitz is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Alan Kivitz have?
ScholarIQindexed works
Alan Kivitz has 348 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Alan Kivitz have?
ScholarIQcitation count
Alan Kivitz has 20,177 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Alan Kivitz?
ScholarIQh-index
Alan Kivitz has an h-index of 76 in OpenAlex.
What is the i10-index of Alan Kivitz?
ScholarIQi10-index
Alan Kivitz has an i10-index of 186 in OpenAlex.
What is the ORCID of Alan Kivitz?
ScholarIQorcid
The ORCID for Alan Kivitz is on the source record.
What is the OpenAlex record for Alan Kivitz?
ScholarIQopenalex
The OpenAlex for Alan Kivitz is on the source record.
What are the most-cited papers on Alan Kivitz?
ScholarIQmost cited works
Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis
Lee S. Simon, Arthur L. Weaver, David Y. Graham, Alan Kivitz, Peter E. Lipsky, Richard C. Hubbard, Peter C. Isakson, Kenneth M. Verburg, Shawn Yu, William W. Zhao, Gilbert Geis
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd‐Ruediger Burmester, David Adams, Lisa Kerr, Chin Lee, Catherine L Shuler, Mark C. Genovese, Khalid Ahmed, Jeffrey Alper, N Barkham, Ralph E. Bennett, Francisco J. Blanco, Ricardo Blanco Alonso, Howard Blumstein, Michael S. Brooks, Gerd‐Rüdiger Burmester, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der‐Yuan Chen, Melvin Churchill, Christine E. Codding, Benard Combe, Peter M.G. Deane, José Del Giudice, Atul Deodhar, Rajat K. Dhar, Eva Dokoupilová, Rita M. Egan, Andrea Everding, E. Galíndez, Mark C. Genovese, David H. Goddard, Alice B. Gottlieb, Philippe Goupille, Robert Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu‐Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan Kivitz, Steven J. Klein, Mariusz Korkosz, Roshan Kotha, Joel M. Kremer, C Lue, José Luís Marenco de la Fuente, Helena Marzo‐Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama Nandagudi, Peter Nash, Antonio Fernández‐Nebro, C. Michael Neuwelt, Ana‐Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria Rell‐Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen‐Fang Tsai, Anthony Turkiewicz, L. Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng-Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielińska
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
Karel Pavelka, Alan Kivitz, Eva Dokoupilová, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Luminita Pricop, Mats Andersson, Aimee Readie, Brian Porter